Renerve Limited · ASX:RNV
Renerve — Q2 FY25 Earnings Presentation
14 slides from Renerve's earnings presentation, Feb 6, 2025
Slide 1: Transforming Nerve Repair Through Science
TRANSFORMING NERVE REPAIR THROUGH SCIENCE For personal use only Quarterly Investor Update February 2025 1
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer Nature of Document: This presentation has been prepared and issued by ReNerve Ltd (Company) to provide general information about the Company. The information in this document is in summary form and should not be relied upon as a complete and accurate representation of a
Slide 3: Executive Summary
Executive Summary Development of Novel Nerve Repair & Regeneration Products ReNerve is focused on developing a portfolio of products for the nerve repair and regeneration markets, with clearly defined commercial demand. For personal use only Significant Product Portfolio ReNerve currently has one pr
Slide 4: ReNerve's Opportunity
ReNerve’s Opportunity Nerve Cuff Nerve Conduit Nerve Guide Matrix Bionic Nerve For personal use only • Used on damaged or transected • Developed using same technology • An ‘off-the-shelf’, ready to use nerve • An ‘off-the-shelf’, continuous nerve Product nerves with no gaps or gap closure (scCOO2) a
Slide 5: Global Nerve Repair Biomaterial Market
Global Nerve Global Nerve Repair Biomaterial Market* Global Market by Segment* Repair $8.0Bn Biomaterial $6.0Bn 32% 16% Market USD $Bn $4.0Bn For personal use only 52% $2.0Bn Nerve Wrap Nerve Conduit - Nerve Grafts 2024 2025 2026 2027 2028 2029 2030 2031 North America Europe Asia Pacific Latin Ameri
Slide 6: NervAlign Nerve Cuff: Quarterly Sales update
NervAlign® Nerve For personal use only Cuff Quarterly Sales update 6
Slide 7: Sales & Marketing
Sales & Marketing Sales Highlights ReNerve Distribution U.S. HONG KONG MIDDLE EAST Sales for Q2 FY25 of A$54K represented ReNerve sales agent in place a +200% increase on sales for the PCP. For personal use only Preliminary unaudited revenue for 1H FY25 increase 176% on the PCP. • Established sales
Slide 8: NervAlign Nerve Cuff: Clinical trial update
NervAlign® Nerve For personal use only Cuff Clinical trial update 8
Slide 9: Key Features Clinical Use
Key Features Clinical Use Product Patient Results • The NervAlign® Nerve Cuff is an FDA cleared product used on • 80% of cases to date have been focused on hand and wrist. damaged or transected nerves with no gaps or gap closure • Clinical cases have: achieved by flexion. ✓ All reported positive out
Slide 10: Clinical Study
Clinical Study • ReNerve has completed an initial clinical study to explore the benefits of using the NervAlign® Nerve Cuff in the repair of injured nerves. • The data will be presented late March at the American College of Foot and Ankle Surgeons conference in Phoenix. For personal use only • Clini
Slide 11: Research & Development Update
NervAlign® Nerve Conduit ReNerve focus is on moving towards commercial manufacturing batches. 1 For personal use only NervAlign® Nerve Guide Matrix ReNerve is focused on progressing through the second stage of commercial development. 2 Research & Development Update 11
Slide 12: Investment Highlights
Investment Highlights IN MARKET PRODUCT IMMEDIATE MARKET NEED GROWING MARKET For personal use only Nerve Cuff transitioned from R&D to Product offering promotes nerve injury Nerve repair biomaterials market is commercial sales post FDA market recovery and regrowth leading to faster forecasted to gro
Slide 13: Near Term Milestones – 2025
Near Term Milestones – 2025 For personal use only Clinical Study Data NervAlign® Nerve Cuff NervAlign® Nerve Progression of the Nerve Guide (March 2025) Approvals in New Conduit into Market Matrix to Stage 3 of Countries & Territories (Q4 2025) Development 1H 2025 2H 2025 Near Term Additional partne
Slide 14: Questions
Questions For personal use only Julian Chick – CEO & Managing Director jchick@renerve.com.au 14